Surgical prognosis of lung invasive mucinous and non-mucinous adenocarcinoma: Propensity score matched analysis

医学 腺癌 倾向得分匹配 内科学 肿瘤科 癌症
作者
Jun Oh Lee,Geun Dong Lee,Sehoon Choi,Hyeong Ryul Kim,Yong‐Hee Kim,Dong Kwan Kim,Seung-Il Park,Jae Kwang Yun
出处
期刊:European Journal of Cardio-Thoracic Surgery [Oxford University Press]
卷期号:66 (3)
标识
DOI:10.1093/ejcts/ezae316
摘要

Abstract OBJECTIVES Invasive mucinous adenocarcinoma exhibits distinct prognostic outcomes compared to non-mucinous adenocarcinoma (ADC). This study investigated and compared the clinical outcomes and prognostic factors of invasive mucinous and non-mucinous ADC patients. METHODS This retrospective study included patients who underwent curative surgery for ADC between 2011 and 2021. Patient characteristics were balanced using propensity score matching. Cumulative incidence was analysed to evaluate cancer recurrence incidence, and the Kaplan–Meier method was used to calculate overall survival (OS) for each group. RESULTS A total of 6101 patients were included. After matching, the non-mucinous group and mucinous groups comprised 798 and 408 patients, respectively. The patients in the mucinous group had a lower recurrence incidence than those in the non-mucinous group (P = 0.014). The recurrence incidence in the mucinous group was between those of grades 1 (P = 0.011) and 2 (P = 0.012) and the OS rates were comparable to those of grades 2 (P = 0.6) and 3 (P = 0.2). Multivariable analysis revealed that the maximal standardized uptake value [hazard ratio (HR): 1.13, P = 0.11] and progressed pathological stages (pStage II, HR: 3.9, P = 0.028; pStage III, HR: 8.33, P = 0.038) served as adverse prognostic factors for the mucinous group. CONCLUSIONS Patients with mucinous ADC demonstrated lower recurrence incidence and similar OS rates compared to those with non-mucinous ADC. The recurrence incidence of mucinous ADC was between those of International Association for the Study of Lung Cancer grades 1 and 2, with the OS rates comparable to those of grades 2 and 3. CLINICAL REGISTRATION NUMBER None.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
天天快乐应助Xifandoufu采纳,获得10
刚刚
归尘发布了新的文献求助30
刚刚
2秒前
2秒前
3秒前
4秒前
luo发布了新的文献求助10
4秒前
4秒前
5秒前
dingding完成签到,获得积分10
5秒前
6秒前
7秒前
科目三应助黄柠檬采纳,获得10
7秒前
依妍发布了新的文献求助10
8秒前
Doc发布了新的文献求助10
9秒前
9秒前
陈小小完成签到,获得积分10
9秒前
小二郎应助枭逍采纳,获得10
10秒前
星辰大海应助傲娇的青荷采纳,获得10
11秒前
BOAy完成签到,获得积分10
11秒前
852应助跳跃鱼采纳,获得10
12秒前
闪闪的谷梦完成签到 ,获得积分10
12秒前
12秒前
luo完成签到,获得积分10
13秒前
酷酷砖头完成签到,获得积分10
13秒前
科研通AI5应助科研通管家采纳,获得10
13秒前
桐桐应助科研通管家采纳,获得10
14秒前
orixero应助科研通管家采纳,获得10
14秒前
天天快乐应助科研通管家采纳,获得10
14秒前
科研通AI5应助科研通管家采纳,获得10
14秒前
李爱国应助科研通管家采纳,获得10
14秒前
赘婿应助科研通管家采纳,获得10
14秒前
wanci应助科研通管家采纳,获得10
14秒前
Xifandoufu发布了新的文献求助10
14秒前
orixero应助谦让幻珊采纳,获得10
15秒前
15秒前
笨笨续完成签到,获得积分10
17秒前
共享精神应助Gser采纳,获得10
18秒前
Pt完成签到,获得积分10
18秒前
19秒前
高分求助中
All the Birds of the World 3000
Weirder than Sci-fi: Speculative Practice in Art and Finance 960
IZELTABART TAPATANSINE 500
Spontaneous closure of a dural arteriovenous malformation 300
GNSS Applications in Earth and Space Observations 300
Handbook of Laboratory Animal Science 300
Not Equal : Towards an International Law of Finance 260
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3720771
求助须知:如何正确求助?哪些是违规求助? 3266756
关于积分的说明 9945954
捐赠科研通 2980459
什么是DOI,文献DOI怎么找? 1634902
邀请新用户注册赠送积分活动 776125
科研通“疑难数据库(出版商)”最低求助积分说明 746155